Let’s give some credit to where credit is due. It has been our team’s hard work and unrelenting energy that has brought the CoolSculpting idea to life. And they are the ones, directly and indirectly, that are about to help you get yours back.
Mark J. Foley
President and Chief Executive Officer
Mark J. Foley has served as President and Chief Executive Officer of ZELTIQ Aesthetics (ZLTQ) since April of 2012. Mr. Foley initially joined ZELTIQ in 2009 as Executive Chairman and as a member of the Board of Directors. Additionally, he serves as a Managing Director at RWIVentures and as Executive Chairman at Onpharma. Prior to this, Mr. Foley held a variety of operating roles in large, public companies and venture-backed startups including US Surgical Corporation, Guidant Corporation, Devices for VascularIntervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO.
Mr. Foley has over 25 years of medical device operating, investment and CEO experience. Additionally, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new companies. Mr. Foley serves or has served as Senior Advisor, Executive Chairman, Interim CEO and Board Member to a number of medical device companies.
Mr. Foley received his B.A. from the University of Notre Dame.
Chief Technology Officer
Len DeBenedictis has served as Chief Technology Officer since October 2012. Mr. DeBenedictis has over 35 years of experience as a high technology pioneer, inventor and senior executive in the medical device and aesthetics industries. Most recently, Mr. DeBenedictis served as Chief Technology Officer at Cutera, Inc, a leading provider of laser and other light-based aesthetic systems, where he led the R&D efforts. Previously, Mr. DeBenedictis served as Chief Technology Officer and Board Member of Solta Medical, a global provider of aesthetic treatments. Prior to Solta, Mr. DeBenedictis served as Co-Founder and Board Member of Reliant Technologies, where he conceived, developed and named the Fraxel Brand skin resurfacing products. Earlier in his career, Mr. DeBenedictis served in various executive and scientific roles at Coherent Medical Group, Coherent Laser Group, Spectra Physics Construction Systems, Atlantic Richfield Development, Xerox and Korad Lasers, the first commercial laser company. Mr. DeBenedictis is an internationally respected inventor with approximately 30 issued US patents.
Senior Vice President, General Counsel and Corporate Secretary
Sergio Garcia has served as Senior Vice President, General Counsel and Corporate Secretary since April 2012. With more than two decades of legal and compliance experience, Mr. Garcia brings a wealth of expertise and knowledge to ZELTIQ. Before joining ZELTIQ, Mr. Garcia was a partner at the law firm Reed Smith LLP from July 2008 to February 2012 and at Fenwick & West LLP October 2005 to July 2008 where he advised public and private emerging growth biotechnology and medical device companies on corporate governance, securities matters, financings, and strategic transactions, including mergers and acquisitions, licensing, joint ventures and international distribution arrangements. Prior to that, Mr. Garcia served as Vice President, Legal and General Counsel at PDL BioPharma Inc. where he was responsible for overseeing the company's legal affairs worldwide, including corporate governance, securities compliance, strategic partnerships, litigation, licensing and mergers and acquisitions activity. Mr. Garcia received his Bachelors of Arts degree in International Relations from Stanford University and his J.D. degree from the University of California, Berkeley, School of Law.
Vice President of Operations
Carl Lamm has served as Vice President of Operations since November 2012 and previously served as Vice President of Manufacturing & Supply Chain from July 2011 to November 2012 and as Senior Director of Supply Chain from April 2008 to July 2011. Prior to joining ZELTIQ, Mr. Lamm served as Manufacturing Manager at Thoratec Corporation, as Operations Manager at Varian Inc. and Director of Logistics and Materials at Orthopedic Technology Inc. With over 25 years of Operations experience in Class II and III Medical Device and High Technology companies managing operations, supply chain and manufacturing functions, Mr. Lamm is now responsible for establishing a flexible, scalable, cost effective and quality driven operations organization. Mr. Lamm holds a BA in Economics from the University of Washington and an M.B.A from Saint Mary’s College.
Keith J. Sullivan
Senior Vice President and Chief Commercial Officer
Keith Sullivan has served as Senior Vice President and Chief Commercial Officer since November 2014. He served as Senior Vice President of Worldwide Sales and Marketing from July 2013 through October 2014. Mr. Sullivan first joined the company as Senior Vice President of Worldwide Sales in October 2012. Mr. Sullivan has more than 30 years of sales experience in the medical device industry. Prior to ZELTIQ, Mr. Sullivan served as Senior Vice President of Commercial Operations of Medicis Technology, a division of Medicis Pharmaceuticals, Inc. While at Medicis, Mr. Sullivan was responsible for developing and implementing the global sales and marketing strategy for LipoSonix, a High Intensity Focused Ultrasound (HIFU) device that subcutaneously treats unwanted fat. Mr. Sullivan later led the Medicis divestiture team, orchestrating the sale of Liposonix to Solta in November 2011. Prior to Medicis, Mr. Sullivan served as Vice President of Global Sales and Channel Marketing of Reliant Technologies, where he was one of five officers responsible for all strategic decisions for Reliant and helped to develop the company's recurring revenue model. Earlier in his career, Mr. Sullivan held sales positions of increasing responsibility at companies such as Medtronic, Vision Quest Laser, Coherent Medical and American V. Mueller, a division of American Hospital Supply. Mr. Sullivan has a Bachelor of Business Administration from the College of William and Mary.
Patrick F. Williams
Senior Vice President and Chief Financial Officer
Patrick F. Williams has served as Senior Vice President and Chief Financial Officer since November 2012. Mr. Williams has nearly 20 years of financial management experience. He spent more than 5 years at NuVasive, most recently as Vice President of Strategy and Investor Relations and previously as Vice President of Finance and Investor Relations. In his most recent position, he worked directly with the company’s Chief Executive Officer and senior management to develop the company’s long-term growth and operational strategy while ensuring alignment across the organization. In his previous role, Mr. Williams was responsible for the day-to-day operations of the finance department including developing the worldwide budget and forecast, identifying profitability improvements, and predicting necessary infrastructure changes to support top-line growth and operating margins. He has had responsibility for managing all aspects of NuVasive’s investor relations efforts as well as significant government affairs duties. Prior to NuVasive, Mr. Williams served as Director of Financial Planning and Analysis at Callaway Golf, where he managed the day-to-day operations of the finance department including budgeting and forecasting, companywide operational analysis and financial reporting. Prior to Callaway, he held senior finance positions at Kyocera Wireless. Mr. Williams holds an MBA in Finance and Management from San Diego State University and a Bachelor of Arts in Economics from University of California, San Diego.
Board of Directors
Mary Fisher has served on our Board since September 2012. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience. Prior to Colorescience, Ms. Fisher was Chief Executive Officer and a Director at SkinMedica from April 2008 to December 2012. Ms. Fisher brings more than 25 years of experience in the pharmaceutical and biotechnology industries including service as Chief Operating Officer of Acorda Therapeutics, a CNS company, with responsibility for corporate strategy and business development, financial planning, sales and marketing, and manufacturing. Previously, Ms. Fisher was Vice President, Strategic Healthcare and Commercial Operations for Cephalon, with responsibility for product planning and marketing, managed care sales, and manufacturing. Her earlier experience includes positions at Immunex and Boehringer Ingelheim. She is also a member of the board of directors of Neuroscience Nursing Foundation.
Mark J. Foley
Mark J. Foley has served on our Board of Directors since July 2009 and has served as the Company’s Executive Chairman of the Board of Directors from July 2009 to May 2010. In this role, Mr. Foley had close interaction with all of the different functional areas and participated in decisions regarding the strategic direction of the Company. Mr. Foley currently serves as a Managing Director of RWI Ventures. While at RWI Ventures, Mr. Foley has led investments in and served on the boards of companies such as BaroSense, Sonitus, and Voyage Medical. Additionally, Mr. Foley serves as Executive Chairman for Onpharma. Prior to joining RWI Ventures in May 2004, Mr. Foley spent 17 years in senior operating roles in both large and start-up medical device companies, most recently founding and serving as Chief Executive Officer of Ventrica, Inc., which was acquired by Medtronic in 2004. Before Ventrica, Inc., Mr. Foley worked for several leading medical device companies, including Perclose (acquired by Abbott), Guidant, DVI (acquired by Eli Lilly), and U.S. Surgical (acquired by Tyco). Mr. Foley received his B.A. from the University of Notre Dame.
D. Keith Grossman
Mr. Grossman brings over 30 years of experience in the medical device industry. He most recently served as Chief Executive Officer, President and a Director of Conceptus, Inc., from December of 2011 until September of 2013, when the company was acquired by Bayer Healthcare for over $1.1 billion. Prior to Conceptus, Mr. Grossman served as a Managing Director of Texas Pacific Group (TPG) Biotech from 2007 to 2011, where he led the medical device practice for the venture capital fund, and also served as a Senior Advisor to the healthcare efforts of the buyout fund, TPG Capital. Before joining TPG, Mr. Grossman was Chief Executive Officer, President and a Director of Thoratec Corporation from 1996 to 2006. During his tenure at Thoratec, revenues grew from $3 million to over $200 million, while market value grew more than twelve-fold to over $1.2 billion. Before joining Thoratec, Mr. Grossman's experience included Sulzermedica and American Hospital Supply Corporation, in a variety of sales, marketing and general management positions. Mr. Grossman still serves on the Board of Directors of Thoratec, as well as the Board of Directors of the Medical Device Manufacturers Association. He is a past member of the Boards of Kyphon, Inc. and Intuitive Surgical, Inc., as well as several private companies. Mr. Grossman received a B.S. in the life sciences from The Ohio State University, and an MBA from Pepperdine University.
Kevin C. O'Boyle
Kevin C. O’Boyle has served on our Board since July 2011. Mr. O’Boyle served as Senior Vice President and Chief Financial Officer at Advanced BioHealing, Inc. from December 2010 until June 2011 when it was acquired. Previously, Mr. O’Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders, from January 2003 to December 2009 and the Executive Vice President of NuVasive from December 2004 to December 2009. Prior to that time, Mr. O’Boyle served as Chief Financial Officer and Chief Operating Officer during his six years with ChromaVision Medical Systems, Inc., a publicly traded medical device firm specializing in the oncology market. Also, Mr. O’Boyle held various positions during his six years with Albert Fisher North America, Inc., a publicly traded international food company, before it was sold in 1996, including Chief Financial Officer and Senior Vice President of Operations. Mr. O’Boyle is currently a member of the board of directors of Tornier N.V., a global orthopedics company, Genmark Diagnostics, Inc., a molecular diagnostics company and Durata Therapeutics, a pharmaceutical company, all publically traded. Mr. O’Boyle received a B.S. in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California at Los Angeles, John E. Anderson Graduate Business School.
Bryan Roberts, PhD
Bryan E. Roberts, PhD has served on our Board of Directors since 2008. Dr. Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as Partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is currently Chairman of the Board at Ironwood Pharmaceuticals, a publicly traded pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines, and also serves on the board of directors of several private companies. Dr. Roberts previously served on the board of directors of Athenahealth, Inc., XenoPort, Inc., and Sirna Therapeutics, Inc. Dr. Roberts received a B.A. from Dartmouth College and a PhD in chemistry and chemical biology from Harvard University.
Andrew Schiff, MD
Andrew N. Schiff, MD has served on our Board of Directors since July 2010. Dr. Schiff joined Aisling Capital in September of 1999 and has served as a Managing Partner since 2002. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, Inc., Colorescience, Dynova Laboratories, Inc., and Planet Technologies, Inc. Previously, Dr. Schiff served as a director of Adams Respiratory Therapeutics, Inc., ArgiNOx Pharmaceuticals, Inc., Barrier Therapeutics, Inc., Bioenvision, Inc., Cempra Pharmaceuticals, Inc., CardioKine, Inc., Miramar Laboratories, Inc., Myogen, Inc., SkinMedica, Inc., Sirion Therapeutics, Inc., and TransEnterix, Inc. Dr. Schiff received his MD from Cornell University Medical College, his MBA from Columbia University, and his BS with honors in Neuroscience from Brown University.
Medical Advisory Board
Jeffrey S. Dover, MD
Associate Clinical Professor of Dermatology, Yale University School of Medicine. Adjunct Professor of Medicine (Dermatology), Dartmouth Medical School. Director, SkinCare Physicians, Chestnut Hill, MA. http://www.skincarephysicians.net
R. Rox Anderson, MD
Professor of Dermatology, Harvard Medical School. Director, Wellman Center for Photomedicine, Massachusetts General Hospital. http://www.massgeneral.org/wellman/
Mathew M. Avram, MD, JD
Director, Massachusetts General Hospital of Dermatology Laser & Cosmetic Center. Faculty Director, Procedural Training in the Department of Dermatology, Harvard Medical School. http://www.massgeneral.org
Eric F. Bernstein, MD, MSE
Director of Laser Surgery and Cosmetic Dermatology Centers, Clinical Associate Professor of Dermatology, University of Pennsylvania. Main Line Center for Laser Surgery. http://dermguy.com/
Brian S. Biesman, MD
Director, Nashville Centre for Laser and Facial Surgery. Clinical Associate Professor, University of Tennessee Health Sciences Center, Memphis, TN. http://www.drbiesman.com
A. Jay Burns, MD, FACS
Assistant Professor, University of Texas Southwestern Medical Center of Dallas. Director, Dallas Medical Skin Care Center, Dallas, TX. http://www.drburns.net
Roy G. Geronemus, MD
Clinical Professor, Department of Dermatology, New York University Medical Center. Director, Laser & Skin Surgery Center of New York, NY. http://www.laserskinsurgery.com
Michael S. Kaminer, MD
Assistant Clinical Professor of Dermatology, Yale Medical School and Adjunct Assistant Professor of Medicine (Dermatology), Dartmouth Medical School. SkinCare Physicians, Chestnut Hill, MA. http://www.skincarephysicians.net
Suzanne L. Kilmer, MD
Associate Clinical Professor, University of California, Davis, School of Medicine. Director, Laser & Skin Surgery Center of Northern California, Sacramento, CA. http://www.skinlasers.com
Dieter Manstein, MD, PhD
Clinical Instructor, Massachusetts General Hospital Department of Dermatology, Harvard Medical School. Co-owner, Bowes Dermatology, Boca Raton, Florida. http://www.bowesdermatology.com
Renato Saltz, MD, FACS
Medical Director & Owner, Saltz Plastic Surgery & Spa Vitoria, Salt Lake City and Park City, UT. http://www.saltzplasticsurgery.com/
Elizabeth L. Tanzi, MD
Clinical Instructor of Dermatology, Johns Hopkins School of Medicine, Baltimore, M.D. Co-Director, Washington Institute of Dermatologic Laser Surgery, Washington, DC. http://www.skinlaser.com
Christopher B. Zachary, MD
Professor and Chair, Department of Dermatology, University of California, Irvine, School of Medicine.
Brian D. Zelickson, MD
Adjunct Associate Professor, Dermatology, University of Minnesota Medical School and Director of the Electron Microscopy Laboratory. Director of Zel Skin and Laser Specialists, Edina, Minnesota and Skin Specialists, Minneapolis and Wayzata, MN. http://www.zelskin.com
Richard Fitzpatrick, MD (in memoriam)
Dr. Richard Fitzpatrick was Associate Clinical Professor, University of California San Diego School of Medicine in the division of Dermatology, Cosmetic Laser Dermatology, San Diego, CA and in private practice at Goldman, Butterwick, Fitzpatrick and Groff Cosmetic Laser Dermatology, La Jolla, CA.
Dr. Fitzpatrick was an internationally recognized Dermatologist and Laser Surgeon, with 36 years of private medical and surgical practice in San Diego. In addition to treating tens of thousands of patients, Dr. Fitzpatrick conducted 130 medical research projects and published over 130 medical papers, 3 medical textbooks and nearly 60 textbook chapters.
Dr. Fitzpatrick passed away on July 12, 2014. We are honored that he served on ZELTIQ’s Medical Advisory Board and shared his knowledge and expertise with many others, which will have a lasting impact on modern medicine and dermatology.